Plain-English translation of NCT07611110 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new radioactive treatment called in people with advanced prostate cancer that has stopped responding to earlier treatments. Researchers want to see if this medication works better than standard treatment options currently available. About 670 people will be randomly assigned to receive either the new treatment or one of three standard care options.
Advanced prostate cancer often becomes resistant to hormone therapy, and patients need new treatment options. This trial exists to see whether this new radioactive medication can help people whose cancer has progressed despite previous treatments, including other radioactive therapies and chemotherapy.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication or one of three standard treatment options chosen by your doctor. You will receive your assigned treatment until your cancer progresses, you experience unacceptable side effects, or your doctor decides to stop for another reason. During and after treatment, you will have regular scans to monitor your cancer, and researchers will follow you throughout the study to track your health and survival.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States